NYSE:MRK
Merck & Company (MRK)
143.93
-0.78 (0.54%)
as of Sep 11, 2026, 8:00:00 pm Market Open.
311 watching
Financials 
Technical Analysis 0
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPAST TOP PICK
(A Top Pick Mar 24/22, Up 5.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRK has triggered its stop at $855. To remain disciplined we recommend covering the position at this time. This will result in a net investment gain of 8%, when combined with previous buy recommendations.
biotechnologypharmaceutical
Premium contentPAST TOP PICK
BUY
Reasonable and sustainable multiple of 12x and very good dividend. Major drug is patent-protected until at least 2026, plus great drugs in pipeline.
Gordon ReidOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick May 08/20, Up 36%) Loves it. A bit pricey here. Model price of $122.65, a 31% upside. In bear markets, people go for predictable earnings. Good bear market stock. Wait for a pullback to buy, under $70. Over 3% yield.
Brian Acker, CAOwned
biotechnologypharmaceutical
Premium contentPAST TOP PICK
TOP PICK
Growth focused, but a real business. Safety. Second-largest in animal health, diversified oncology. Visibility and pricing power. Roche's miss in immunotherapy reinforces MRK's leadership position in that area. Not expensive. 13x earnings for near double-digit EPS growth. Yield is 3.09%. (Analysts’ price target is $96.34)
Paul MacDonaldOwned
biotechnologypharmaceutical
TOP PICK
Their major drug in oncology treats cancer and will earn $18 billion in revenue this year. Trades at 12x earnings and pays a large dividend. MRK has a strong balance sheet, their drug pipeline promises future growth, their balance sheet is strong, and they can resist hot inflation. (Analysts’ price target is $96.34)
Gordon ReidOwned
biotechnologypharmaceutical
BUY
He's long this. You're finally getting a technical breakout. The stock is at the highest levels of the year. Take advantage of the valuation discount for the healthcare sector compared to the S&P.
Joe TerranovaOwned
biotechnologypharmaceutical
Premium contentTOP PICK
Stockchase Research Editor: Michael O’Reilly With several developmental cancer drugs continuing to make good progress, we again reiterate this $195 billion marketcap global drug manufacturer as a TOP PICK. Recently reported earnings beat expectations by over 20% and the company is managing a ROE over 45%. Trading at 16x forward earnings, compared with its peers at 21x, it is good value here. It pays a good dividend, backed by payout ratio under 55% of cash flow. We recommend trailing up the stop (from $70) to $74, looking to achieve $92.50 -- upside potential of 15%. Yield 3.4% (Analysts’ price target is $92.38)
biotechnologypharmaceutical
HOLD
Good large cap with reasonable growth. Really likes its diversity. Oncology, diabetes, immunology, globally #2 in animal health. Competition from BMY and LLY. Lacklustre R&D. Happy to hold through the volatility.
Paul MacDonaldOwned
biotechnologypharmaceutical
Premium contentTOP PICK
Stockchase Research Editor: Michael O'Reilly This $195 billion marketcap global drug manufacturer has just received FDA emergency approval for an oral COVID-19 treatment and is reiterated as a TOP PICK. Japan just committed to 200,000 doses of the new pill. Trading at 11x forward earnings, compared with its peers at 19x, it is good value here. It pays an excellent dividend, backed by payout ratio under 50% of forward cash flow. We recommend trailing up the stop (from $65) to $70, looking to achieve $92.50 -- upside potential of 19%. Yield 3.59% (Analysts’ price target is $92.31)
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
